Navigation Links
Endo Pharmaceuticals to Announce Second Quarter 2011 Financial Results on August 9, 2011
Date:7/26/2011

CHADDS FORD, Pa., July 26, 2011 /PRNewswire/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today announced that it will host a conference call and live Internet webcast on Tuesday, August 9, 2011 at 8:30 a.m. ET to discuss results for the 2011 second quarter.  

David P. Holveck, president and CEO, Julie McHugh, chief operating officer, Dr. Ivan Gergel, executive vice president of R&D, Alan Levin, executive vice president and chief financial officer, Tony Bihl, group president, American Medical Systems, and Blaine Davis, vice president, corporate affairs will host the call.

Investors and other interested parties may call 866-203-2528 (domestic) or 617-213-8847 (international) and enter passcode 76257989.  Please dial in 10 minutes prior to the scheduled start time.

A replay of the call will be available from August 9, 2011 at 12:30 p.m. ET until 12:00 p.m. ET on August 23, 2011 by dialing 888-286-8010 (domestic) or 617-801-6888 (international) and entering passcode 82161745.

A simultaneous webcast of the call may be accessed by visiting www.endo.com.  In addition, a replay of the webcast will be available until 12:00 p.m. ET on August 23, 2011.  The replay can be accessed by clicking on "Events" in the Investor Relations section of the website.

About Endo

Endo Pharmaceuticals is a U.S.-based, specialty healthcare solutions company, focused on high-value branded products and specialty generics. Endo is redefining its position in the healthcare marketplace by anticipating and embracing the evolution of health decisions based on the need for high-quality and cost-effective care. We aim to be the premier partner to healthcare professionals and payment providers, delivering an innovative suite of complementary diagnostics, drugs, devices and clinical data to meet the needs of patients in areas such as pain, urology, oncology and endocrinology. For more information about Endo Pharmaceuticals, and its wholly owned subsidiaries American Medical Systems, Inc., HealthTronics, Inc. and Qualitest Pharmaceuticals, please visit http://www.endo.com/.


'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Feb 23, 2017 ... Research and Markets has announced the addition of ... to 2025" report to their offering. The Global ... 1.8% over the next decade to reach approximately $12.8 billion by 2025. ... forecasts for all the given segments on global as well as regional ...
(Date:2/23/2017)... , February 23, 2017 ... on the global market for intraoperative imaging, excerpts ... valued at US$ 513.9 million. According to the ... surging on the grounds of increasing adoption of ... field of diagnostic imaging for neurosurgeries. The world,s ...
(Date:2/23/2017)... LG Innotek today announced that the company has developed ... sterilization performance is 1.5 times higher than the competitor,s 45mW module. ... the range of 200 -- 280nm, allowing it to be used for ... DNA. LG Innotek,s product emits UV in the range of 280nm. ... Until now, UV-C ...
Breaking Medicine Technology:
(Date:2/23/2017)... Boulder, CO (PRWEB) , ... February 23, 2017 , ... ... to announce the winner of the 2016 National Education Policy Center Bunkum Award. We ... report reviewed in 2016. , This year’s Bunkum winner is the Center for American ...
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., ... From Not to Hot,” which will begin airing on February 24, 2017. The show ... from the 2012 reality television series, “Here Comes Honey Boo Boo.” The earlier series ...
(Date:2/23/2017)... ... February 23, 2017 , ... On ... a diverse symposium on “Doping in Sport: How the Culture Might Change,” ... & Hampton LLP. The symposium will be held at Pepperdine University in Malibu, ...
(Date:2/23/2017)... ... February 23, 2017 , ... Current Meditation ... soon begin franchising throughout the U.S. starting this spring. Current Meditation focuses on ... of meditation mainstream. Current Meditation will be the first meditation concept in the ...
(Date:2/23/2017)... ... February 23, 2017 , ... CALNOC, the nation’s first and only ... their upcoming conference – Empowerment, Value and Collaboration – in Seattle, WA on October ... the Virginia Mason Health System in Seattle since 2000. In addition to his role ...
Breaking Medicine News(10 mins):